Search

Your search keyword '"Pickering, Lisa"' showing total 318 results

Search Constraints

Start Over You searched for: Author "Pickering, Lisa" Remove constraint Author: "Pickering, Lisa"
318 results on '"Pickering, Lisa"'

Search Results

2. A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM)

3. Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma

5. REFINE (REduced Frequency ImmuNE checkpoint inhibition in cancers): A multi-arm phase II basket trial testing reduced intensity immunotherapy across different cancers

6. Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study

7. The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment: Including myocarditis and the new entity of non inflammatory left ventricular dysfunction

9. Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study

10. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study

11. Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study

13. Perspectives on Neoadjuvant Clinical Trial Participation for Patients with Kidney Cancer: A Survey-Based Examination

14. Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM)

15. A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM)

17. Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study

18. Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM).

19. Data from Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways

20. Supplementary Tables S1-S8 from Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways

21. Supplementary Figures S1-S25 from Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways

22. Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer

23. Supplementary Tables and Figures from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma

24. Supplementary Figure 4a from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma

25. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial

26. Late-stage metastatic melanoma emerges through a diversity of evolutionary pathways

27. Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study

29. Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer

30. Oral beclomethasone dipropionate is an effective treatment for immune checkpoint inhibitor induced colitis

32. Longitudinal cohort analysis of patients with metastatic penile cancer treated in a large quaternary academic centre.

33. The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment

34. Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer

35. Abstract PR002: Advanced melanoma exhibits a diversity of evolutionary routes to lethality

36. Abstract A012: Advanced melanoma exhibits a diversity of evolutionary routes to lethality

37. Clinical Models to Define Response and Survival With Anti–PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma

38. Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer

39. Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay

40. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study

41. Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study

42. Real-World Outcomes with Ipilimumab and Nivolumab in Advanced Melanoma: A Multicentre Retrospective Study

43. Immune responses following third COVID-19 vaccination are reduced in patients with hematologic malignancies compared to patients with solid cancer

44. Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma

45. Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial

46. Angiokines associated with outcomes after sunitinib or everolimus treatment in patients with non-clear cell renal cell carcinoma

47. Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma

48. VinCaP: a phase II trial of vinflunine in locally advanced and metastatic squamous carcinoma of the penis

49. mTOR and VEGF Tissue Biomarkers and Sunitinib/Everolimus Outcomes in Non-Clear Cell Renal Cancer

50. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study

Catalog

Books, media, physical & digital resources